FINNENCE ▪ THE WIRE FILE
THE WIRE · № 76378
News▲ Bullish
New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
KINDNews
DIRECTION▲ Bullish
SOURCES2
ENTITIES2
STORY SIZE2 RECORDS
FIRST SEEN
LAST UPDATE
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Consistent fistula remission across hard-to-treat subgroups supports expanded use in Crohn's disease.
Fistula data broadens Crohn's positioning
CATALYST TO WATCH
Regulatory filings for expanded indication
MAIN RISK
Small subgroup sizes limit statistical weight
FULL DISPATCH
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST · LAST2026-10-12 20:05 UTCNewsNew TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroupsCURRENT RECORD
2026-10-12 20:05 UTCNewsTREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDJohnson & Johnson · JNJ
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare, JNJ
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease2026-10-12 20:05 UTC
TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease2026-10-12 20:05 UTC
→CORRELATIONshares Healthcare
Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care2026-10-12 20:25 UTC
Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care2026-10-12 20:25 UTC
→CORRELATIONshares Healthcare
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus2026-10-12 20:30 UTC
ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett's Esophagus2026-10-12 20:30 UTC
→CORRELATIONshares Healthcare
Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust Fight2026-10-12 20:58 UTC
Corcept Seeks to Block Ex-Judge’s Testimony in Teva Antitrust Fight2026-10-12 20:58 UTC
←CORRELATIONshares Healthcare
Parkinson’s cell therapy developer files to go public2026-10-12 16:18 UTC
Parkinson’s cell therapy developer files to go public2026-10-12 16:18 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.